562103-08-6

Basic information

• Product Name: 1-Butanol, 2-[[(3-fluorophenyl)methylene]amino]-3-methyl-, (2R)-
• CAS NO: 562103-08-6
• Molecular Formula: C12H16FNO
• Molecular Weight: 209.264
• Mol File: 562103-08-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Butanol, 2-[[(3-fluorophenyl)methylene]amino]-3-methyl-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Butanol, 2-[[(3-fluorophenyl)methylene]amino]-3-methyl-, (2R)-(562103-08-6)
• EPA Substance Registry System: 1-Butanol, 2-[[(3-fluorophenyl)methylene]amino]-3-methyl-, (2R)-(562103-08-6)

Safety Data

• Hazardous Substances Data: 562103-08-6(Hazardous Substances Data)

Usage

Structure

1-Butanol derivative with a substituted fluorophenylmethyleneamino group
The compound is derived from 1-butanol, with an additional fluorophenylmethyleneamino group attached.

Stereochemistry

(2R)-
The stereochemistry of the molecule is designated as (2R)-, indicating that the substituent attached to the second carbon is in the R configuration.

Potential Applications

Pharmaceuticals, organic synthesis, industrial processes
The compound may have various applications in different fields, such as the development of new drugs, organic synthesis, or other industrial applications.

Safety Precautions

Handle with care, hazardous properties, proper safety protocols
Due to its potential hazardous properties, it is crucial to handle this chemical with care and follow appropriate safety protocols to minimize risks.

Upstream product

• 4276-09-9 (R)-2-amino-3-methylbutanol 
• 456-48-4 3-Fluorobenzaldehyde 

Downstream Products

• 473732-83-1 C₁₅H₂₄FNOSi 

Relevant articles and documents

New quinoline NK3 receptor antagonists with CNS activity

Lead optimisation starting from the previously reported selective quinoline NK3 receptor antagonists talnetant 2 (SB-223412) and 3 (SB-222200) led to the identification of 3-aminoquinoline NK3 antagonist 10 (GSK172981) with excellent CNS penetration. Investigation of a structurally related series of sulfonamides with reduced lipophilicity led to the discovery of 20 (GSK256471). Both 10 and 20 are high affinity, potent NK3 receptor antagonists which despite having different degrees of CNS penetration produced excellent NK3 receptor occupancy in an ex vivo binding study in gerbil cortex.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.